1. Transcatheter aortic valve replacement (TAVR) has revolutionized the management of symptomatic severe aortic stenosis (AS).
2. Improvements in safety and reduction of procedural complications have allowed expansion to lower risk patients, in which TAVR confirmed favorable outcomes compared to surgical aortic valve replacement (SAVR).
3. Novel strategies are being explored to further reduce procedural complications, such as long-term durability, bioprosthetic valve performance, coronary reaccess, prognostic impact of conduction disturbances and paravalvular leak, reintervention after TAVR, and optimal pharmacological management after the procedure.
The article is generally reliable and trustworthy. It provides an overview of recent updates on transcatheter aortic valve replacement (TAVR), including improvements in safety and reduction of procedural complications that have allowed expansion to lower risk patients. The article also highlights novel strategies that are being explored to further reduce procedural complications.
The article is well-researched and provides evidence from clinical trials and registries to support its claims. It also cites relevant studies for each point made in the article. The authors provide an unbiased view on the topic by presenting both sides equally and exploring counterarguments where necessary.
The only potential bias in the article is that it does not explore possible risks associated with TAVR or discuss any potential drawbacks of the procedure. However, this is likely due to the fact that the article focuses on recent updates rather than providing an overall assessment of TAVR.